CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

The deal with NBE includes a $25 million upfront payment ... a license to an ADC developed by Iconic Therapeutics – called ICON-2 – which targets the tissue factor (TF) pathway thought to ...

The site in the European biotech hub of Basel, Switzerland, is run by Boehringer’s subsidiary NBE Therapeutics. Boehringer bought the Swiss biotech for $1.5 billion in 2020 in a deal centered ...

NBE-Therapeutics’ immune-stimulatory antibody drug conjugates (iADCs) have a novel mode of action that makes them uniquely well-equipped to fight cancer. iADCs target and destroy cancer cells ...